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Summary
The development of inhibitors to replacement factor therapy is a serious complication in the
treatment of patients with haemophilia and requires use of bypassing agents to prevent
uncontrolled bleeding. The efficacy of recombinant factor VIIa (rFVIIa) as a bypassing agent in
patients with haemophilia has been demonstrated in case studies and clinical trials. However, the
perception of a short plasma half-life and consequent need for repeated daily injections means that
long-term prophylaxis could potentially be limiting. Canine haemophilia models using a gene
transfer approach have been used to evaluate the continuous expression of FVIIa in dogs. These
studies show improvement in measurable bleeding parameters that have important clinical
ramifications for patients with haemophilia. The combination of gene transfer as the method of
delivery and FVII as the transgene overcomes issues associated with the short plasma half-life of
rFVIIa, and represents a potentially attractive novel approach to haemostasis in patients with
haemophilia and other platelet disorders.
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Introduction
Antibodies (inhibitors) that inhibit or inactivate replacement therapy with factor VIII (FVIII)
(or factor IX [FIX]) remain one of the most serious complications affecting patients with
haemophilia [1–3]. The development of inhibitors occurs in 20–30% of patients with
haemophilia A and in around 5% of patients with haemophilia B [4]. In those patients who
have high-responding inhibitors, traditional factor replacement therapy is often ineffective
[5] and patients are treated with bypassing therapy [6].
Recombinant factor VIIa ([rFVIIa]; NovoSeven®; NovoNordisk, Bagsvaerd, Denmark) is
considered a bypassing agent [5,7] meaning that it bypasses the usual coagulation process or
pathways that utilize FVIII and FIX to generate a blood clot. Data from a series of case
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reports in secondary prophylaxis show that rFVIIa in haemophilia patients with inhibitors
and a high bleeding tendency reduces the number and severity of bleeds and improves joint
status/quality of life, without evidence of pathological thrombosis or adverse events [8–12].
A further study (the only randomized, prospective clinical trial of a bypassing agent) has
investigated the efficacy and safety of rFVIIa for secondary prophylaxis of 22 patients with
severe haemophilia A or B with inhibitors. In this study, bleeding frequency was reduced
during prophylaxis with 90 μg kg−1 or 270 μg kg−1 daily and the majority of the reduction in
bleeds was maintained during post-prophylaxis, with no thromboembolic events reported
[13]. Additionally, rFVIIa has been used effectively to control bleeding in haemophilia
patients with inhibitors undergoing surgery [14].
Irrespective of these data outlining the efficacy and safety of rFVIIa in prophylactic
regimens, the perception remains that the short plasma half-life [15] and consequent need
for repeated daily injections will limit its use for prolonged periods of prophylaxis [16]. This
article reviews the work of several investigators who have used animal models of gene-
based therapy approaches to study the effect of continuous expression of FVIIa [17].
Murine models of FVII transgene therapy
Relatively few data on the haemostatic effects of continuously elevated FVIIa levels are
available. To address this issue, Margaritis et al. tested a modified FVIIa transgene in a
murine model to investigate whether FVIIa continuously expressed is able to achieve
adequate haemostasis without promoting pathological thrombosis [17]. In this study a
human FVII (hFVII) transgene containing a cleavage site for the intracellular protease,
paired amino acid-cleaving enzyme/furin, was shown to be correctly processed
intracellularly and secreted as human-activated FVII (hFVIIa). This construct was
introduced into a recombinant adeno-associated virus (AAV) vector and shown to direct
long-term, high-level expression in normal mice. Levels of approximately 2 μg mL−1 could
be obtained; these levels are comparable to those obtained in patients after dosing with
rFVIIa [15].
Using these data as a guide, the hFVII was switched to a vector encoding an engineered
murine FVII (mFVII) to resolve an important difference between the two species of
insufficient binding of hFVIIa to murine tissue factor. The mFVII vector was introduced
into the hepatic circulation of normal and haemophilia B C57BL/6 animals resulting in long-
term expression of mFVIIa. A sustained reduction in both the prothrombin clotting time
(PT) and activated partial thromboplastin time (aPTT) was observed. The clotting times
were lowered to levels typically observed in the normal range. The reduction in aPTT is
because of the high concentration of circulating rFVIIa which, through interaction with
phospholipids in the aPTT reagents, is capable of inducing thrombin generation and results
in a shortening of the clotting time. In addition, the use of a murine transgene allowed the
evaluation of haemostasis in the haemophilic mouse model in response to a haemostatic
challenge in vivo (tail clip assay). The tail clip assay showed that the mFVIIa levels
achieved (approximately 1 μg mL−1) were sufficient to reduce bleeding substantially in all
treated haemophilia B mice compared with untreated animals. No influence on survival (at 6
months) was observed, and no biochemical evidence of increased risk of thrombosis
compared with untreated haemophilia B controls was reported [17].
The modified FVII transgene permits the evaluation of whether low levels of FVIIa,
continuously expressed, would be sufficient to achieve haemostasis without promoting
thrombosis – a hypothesis tested in a study by Aljamali et al. [18]. In this study transgenic
mice that expressed a range of mFVIIa levels (categorized as low and high expressors based
on plasma levels of mFVIIa) were generated and crossed with mice with haemophilia B. The
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data showed that when mFVIIa was continuously expressed in transgenic mice, even low
levels were sufficient to improve haemostasis and expression of mFVIIa at levels in the
range of 0.3 μg mL−1(6 nM) to 1.5 μg mL−1 (30 nM) were compatible with a normal
lifespan. However, over-expression of mFVIIa at levels exceeding 2 μg mL−1 (40 nM)
caused early mortality in normal and haemophilic mice possibly because of cardiac and
pulmonary side effects. These results suggested ranges for haemostatic efficacy of
continuously expressed mFVIIa and defined upper limits for safety in mice [18].
Canine model of gene-based FVIIa expression
To investigate whether the positive effects of gene transfer observed in murine models
translate to large animals, Margaritis et al. [16] used the canine haemophilia model to
evaluate gene-based, AAV-mediated continuous expression of canine FVIIa (cFVIIa) as a
treatment for haemophilia. Canine models have been extensively applied in haemostasis
research and are considered valid models in relation to human coagulation factor
deficiencies, particularly haemophilia A and B.
Efficacy of AAV-mediated cFVII gene transfer
A serotype 8 AAV vector (AAV8-cFVII) was generated that directed expression of cFVIIa
via a liver-specific promoter in a similar manner to that described in previous murine studies
[17,18]. To test the AAV vector, tail vein vector administration in mice with haemophilia
was performed, which demonstrated that expression of cFVIIa resulted in long-term,
sustained haemostatic functionality as shown by normalization of the haemophilic aPTT and
concurrent supraphysiological shortening in the PT. The next experiment was the infusion of
the AAV8-cFVII vector (6.25–12.5E13 vg kg−1) into haemophilia A and haemophilia B
dogs which led to a long-term, stable reduction for both whole blood clotting time (WBCT)
and PT as a result of sustained canine FVIIa (cFVIIa) expression that ranged between 1.3
and 2.6 μg mL−1 (P < 0.03 vs. normal or untreated haemophilia A or B dogs). Moreover,
thromboelastography analysis of whole blood from these dogs with haemophilia A or B
showed improved clot dynamics and a sustained, near-normalization of the reaction time
(time to initial fibrin formation) vs. normal dogs [16].
Spontaneous bleeding episodes in AAV-cFVII-treated haemophilic dogs
The number of spontaneous bleeds was also evaluated as a measure of clinical efficacy as
dogs with haemophilia are known to exhibit these types of bleeds several times per year.
Untreated dogs with haemophilia A and B observed concurrently within the study exhibited
12 and 21 spontaneous bleeds in 36 and 60 months of observation respectively. In
comparison, during 34-month (haemophilia B) and 45-month (haemophilia A) observation
periods, the AAV8-cFVII-treated dogs did not exhibit any spontaneous bleeding episodes
[16].
Safety of long-term cFVIIa expression in AAV-treated haemophilic dogs
Analysis showed that serum chemistries for liver and kidney functions were within the
normal range in all dogs before and after gene transfer. Platelet counts were within the
normal range throughout the study and levels of thrombin-antithrombin (TAT) complex and
D-dimer levels (elevated levels of which are indicators of intravascular fibrin forming
processes) did not change significantly throughout the observation period relative to pre-
AAV administration levels. Fibrinogen levels displayed some variability. These findings in a
limited numbers of dogs indicate that continuous cFVIIa expression had a good safety
profile in this study [16].
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Continuous expression of cFVIIa in dogs with haemophilia provides proof-of-concept for
the gene transfer approach investigated. Data reported are similar to those observed in
transgenic haemophilic mice (mFVIIa) and haemophilic mice receiving AAV-mFVII-
mediated gene transfer [17,18]. Circulating plasma levels of cFVIIa in the range of 1.5–2.5
μg mL−1 were obtained, and led to supraphysiologically reduced PT as well as significantly
improved throm-boelastography measurements. More importantly, no spontaneous bleed
was observed in these dogs. Taken together these results, in conjunction with the murine
model data, suggest haemostatic efficacy similar to levels achieved with bolus rFVIIa
infusion in humans [16].
Animal model data demonstrate that liver-directed, AAV8-mediated gene transfer of mFVII
or cFVII in haemophilia A and B leading to continuous expression of FVIIa is effective and
safe in the short-and medium-term, and results in improvement in measurable bleeding
parameters that have important clinical ramifications for patients with haemophilia. The
combination of gene transfer as the method of delivery and FVII as the transgene obviates
any issues relating to tolerance (immunological) and the short plasma half-life of rFVIIa,
and represents a potentially attractive novel approach to haemostasis in patients with
haemophilia and other platelet disorders.
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